Abstract
Introduction: With the advent of the COVID-19 pandemic, extensive efforts have begun worldwide to identify the factors that reduce the incidence of the disease. Various methods have been launched to combat the disease. Changes in serum immunoglobulin levels are among the factors that have been considered in COVID-19.
Objectives: The aim of this study was to determine the changes in IgG levels in patients diagnosed with COVID-19 in 2020 at Al-Zahra hospital in Isfahan.
Patients and Methods: In this prospective study, 65 patients with COVID-19 were evaluated. Their serum IgG levels were assessed before and at three and six months after the start of treatment, and changes in the levels of this immunoglobulin before and after treatment were compared.
Results: The mean IgG level at the time of referral was 1214.2±672.1 mg/dL and increased to 1490.8 ±621.5 mg/dL at the three months after treatment. At six months after treatment, IgG levels decreased compared to three months later and reached 1375.1±609.1 mg/dL. There was a significant difference in changes in IgG levels during the six months after the onset of the disease compared to repeated measures analysis of variance (P=0.001).
Conclusion: The present study’s findings showed that IgG levels increased significantly in three months after COVID-19 and decreased significantly in 6 months. Since IgG levels begin to rise at least four weeks after exposure to the virus, this immunoglobulin cannot be conducted as a diagnostic tool to detect COVID-19.